NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
20 trialsNCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT06080204 2023-10-18
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Phase NA Completed
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT04129255 2020-09-10
CSMS99
National Cancer Institute, Naples
Phase 2 Completed
NCT04140409 2019-10-25
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 4 Terminated
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03057509 2019-06-21
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Phase 1 Withdrawn
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated